Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
Sponsor: Drugs for Neglected Diseases
A PHASE3 clinical study on Visceral Leishmaniasis, this trial is completed. The trial is conducted by Drugs for Neglected Diseases and has accumulated 11 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Mar 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Aug 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Drugs for Neglected Diseases
- Kenya Medical Research Institute
- Makerere University
- The Institute of Endemic Diseases (IEND), University of Khartoum
- The Netherlands Cancer Institute
- University of Gondar
For direct contact, visit the study record on ClinicalTrials.gov .